A gene therapy vector nucleic acid construct for allergic diseases and its use method
The genes of anti-IgE antibodies are loaded through adeno-associated viral vectors, which solves the problems of inefficiency and insufficient durability of allergic asthma and chronic spontaneous urticaria, and achieves efficient and lasting treatment effects of allergic diseases.
Patent Information
- Application Number
- CN202310849120.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-11
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-07-11
AI Technical Summary
The prior art is difficult to effectively treat or prevent allergic asthma and other allergic diseases, and traditional methods have problems of inefficient efficiency, high cost and insufficient treatment durability.
Adeno-associated viral vector was developed, including expression cassette structures, including promoters, signal peptide coding sequences, heavy chain and light chain coding sequences of anti-IgE antibodies, and adeno-associated viral gene therapy vectors were used for higher efficiency and lower cost. Production of gene therapy for allergic diseases.
Achieving high-level gene expression of purpose provides a more effective, safe and long-lasting method to treat or prevent allergic asthma and chronic spontaneous urticaria. By long-term continuous expression of anti-IgE antibodies, it significantly reduces the alveolar lavage fluid. Eosinophil ratio, relieves asthma symptoms.
Smart Images

Figure CN116790615B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and more specifically, to a gene therapy vector nucleic acid construct for allergic diseases and a method of using the same. The gene sequence construct can be used for gene therapy of allergic diseases such as chronic spontaneous urticaria and allergic asthma. The gene sequence construct can be used to produce adeno-associated virus gene therapy vectors for the gene therapy of the above-mentioned allergic diseases with higher efficiency and lower cost. Background Art
[0002] Allergic asthma is a chronic respiratory disease with reversible airflow obstruction, which is associated with excess mucus and airway remodeling. It is common in children, with a reported prevalence of 5-15%. In the past few decades, the prevalence and mortality of asthma have been increasing worldwide, with approximately 250,000 patients dying from the disease each year, affecting 300 million people worldwide. The disease is caused by immune dysfunction, mainly affected by effector T cell subsets, and is characterized by chronic airway inflammation involving multiple cellular components (such as eosinophils, mast cells, T lymphocytes, neutrophils, airway epithelial cells, etc.). This chronic inflammation is associated with airway remodeling and airway hyperresponsiveness, usually with extensive and variable reversible expiratory airflow limitation, leading to recurrent symptoms of wheezing, shortness of breath, chest tightness and / or cough, which vary in intensity over time. It is a heterogeneous disease with multiple phenotypes. In addition to inflammation caused by increased airway eosinophilia, increased Th2 cells, and excessive secretion of type 2 cytokines IL-4, IL-5, and IL-13, allergic asthma patients also have a phenotype characterized by increased serum allergen IgE levels. Although most patients respond well to safe and evidence-based stepwise drug treatment, less than 5% of asthma patients show a severe treatment-resistant asthma phenotype.
[0003] Studies have shown that the autoimmune mechanism of most allergic asthma patients involves the high-affinity receptor FcεRI for the Fc region of IgE. IgE is the main immunoglobulin that mediates type I allergic reactions. When IgE binds to the high-affinity receptor FcεRI on the surface of mast cells or basophils, it causes mast cells or basophils to degranulate, followed by the release of some bioactive mediators, such as histamine, proteases and cytokines, and the production of platelet-activating factor and other arachidonic acid metabolites (prostaglandin D2, leukotrienes C4, D4 and E4). These mediators can cause airway smooth muscle contraction, capillary dilation and increased permeability, and increased glandular secretions, which together induce early and late allergic reactions and have a serious negative impact on the quality of life of asthma patients.
[0004] Since increased serum specific IgE levels are the main feature of allergic asthma and one of the key links in the pathogenesis of allergic diseases such as asthma. Therefore, how to reduce the specific IgE level in asthma patients has become a research focus for asthma prevention and treatment, and anti-IgE therapy is expected to provide a new and effective treatment for asthma patients. In 2003, omalizumab monoclonal antibody was the first humanized monoclonal antibody for anti-IgE therapy and was approved in the United States for the treatment of moderate to severe persistent allergic asthma. Omalizumab can bind to the constant region (Cε3) of the IgE molecule and prevent free IgE from binding to its receptor, reducing the release of bioactive mediators. At the same time, the reduction of serum free IgE leads to the downregulation of FcεRI surface expression on effector cells, further inhibiting the response of effector cells to allergens. In controlled clinical studies, the correlation between free IgE levels and asthma symptoms shows that greater suppression of IgE can bring better clinical benefits. Ligelizumab (QGE031) is another fully humanized monoclonal IgG1 antibody targeting human IgE, which binds to the Cε3 domain of IgE with higher affinity than omalizumab. Compared with omalizumab, ligelizumab has a stronger and more sustained inhibitory effect on free IgE on the surface of mast cells and basophils, which helps to better block the allergic cascade and improve the clinical effect of treating asthma. In addition to the above two anti-IgE monoclonal antibody drugs, the current treatment strategies for allergic asthma also include antihistamines, leukotriene receptor antagonists, β2-adrenergic receptor agonists and glucocorticoids. The latter only provides temporary relief by inhibiting inflammatory responses and has certain side effects.
[0005] Therefore, there is an urgent need in the art to develop a more effective, safe and lasting method for treating or preventing allergic asthma and even other allergic diseases. Summary of the invention
[0006] The purpose of the present invention is to provide a more effective, safe and lasting method for treating or preventing allergic asthma and even other allergic diseases.
[0007] In the first aspect of the present invention, an expression cassette is provided, which comprises the following elements: a promoter, an optional first signal peptide coding sequence, an anti-IgE antibody heavy chain coding sequence, an optional linker sequence, an optional second signal peptide coding sequence, and an anti-IgE antibody light chain coding sequence.
[0008] In another preferred embodiment, the linker includes one or more selected from the following group: self-cleavage linker, Furin cleavage site, IRES linker.
[0009] In another preferred embodiment, the anti-IgE antibody is selected from the following group: Ligelizumab, Omalizumab, or a combination thereof.
[0010] In another preferred embodiment, the expression cassette has a structure shown in Formula I from the 5' end to the 3' end:
[0011] Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9 (Formula I)
[0012] in,
[0013] Each "-" is independently a bond or a nucleotide linking sequence;
[0014] Z1 is the promoter;
[0015] Z2 is an optional first signal peptide coding sequence;
[0016] Z3 is the heavy chain coding sequence of the anti-IgE antibody;
[0017] Z4 is the Furin cleavage site;
[0018] Z5 is the coding sequence of the self-cleaving linker;
[0019] Z6 is an optional second signal peptide coding sequence; and
[0020] Z7 is the light chain coding sequence of the IgE antibody;
[0021] Z8 is an optional woodchuck hepatitis virus regulatory element WPRE element;
[0022] Z9 is an optional polyadenylation signal (polyA).
[0023] In another preferred embodiment, the expression cassette has a structure shown in Formula II from the 5' end to the 3' end:
[0024] Z1-Z2-Z3-Z4'-Z6-Z7-Z8-Z9 (Formula I)
[0025] Wherein, Z1, Z2, Z3, Z6, Z7, Z8, and Z9 are defined as above, and Z4' is an IRES element;
[0026] Each "-" is independently a bond or a nucleotide linking sequence.
[0027] In another preferred embodiment, the promoter is an enhanced promoter, including: CMV, CBH, EF1α, CAG, CAGG, CAS I, desmin, TMCK, MCK, MHCK7, PGK, TTR.
[0028] In another preferred embodiment, the nucleotide sequence of the CBH promoter has ≥95% identity with the nucleotide sequence shown in SEQ ID NO.1, preferably ≥98%, and more preferably ≥99%.
[0029] In another preferred example, the nucleotide sequence of the CBH promoter is shown in SEQ ID NO.:1.
[0030] In another preferred example, the first signal peptide and the second signal peptide are each independently selected from the following group: SAP signal peptide, IHC signal peptide, ILC signal peptide, AP signal peptide, CSP signal peptide, IL2 signal peptide, TPA signal peptide, L1 signal peptide, H7 signal peptide, or a combination thereof.
[0031] In another preferred example, the nucleotide sequence of the heavy chain coding sequence of the IgE antibody is as shown in SEQ ID NO: 2, or has a sequence identity of more than 90% (preferably more than 95%, more preferably more than 96%, more than 97%, more than 98% or more than 99%) thereto.
[0032] In another preferred example, the amino acid sequence of the heavy chain of the IgE antibody is as shown in SEQ ID NO.: 3, or has a sequence identity of more than 90% (preferably more than 95%, more preferably more than 96%, more than 97%, more than 98% or more than 99%) thereto.
[0033] In another preferred example, the nucleotide sequence of the light chain encoding sequence of the IgE antibody is as shown in SEQ ID NO:4, or has a sequence identity of more than 90% (preferably more than 95%, more preferably more than 96%, more than 97%, more than 98% or more than 99%) thereto.
[0034] In another preferred example, the amino acid sequence of the light chain of the IgE antibody is as shown in SEQ ID NO:5, or has a sequence identity of more than 90% (preferably more than 95%, more preferably more than 96%, more than 97%, more than 98% or more than 99%) thereto.
[0035] In another preferred embodiment, the heavy chain coding sequence of the IgE antibody is a codon-optimized sequence.
[0036] In another preferred embodiment, the light chain coding sequence of the IgE antibody is a codon-optimized sequence.
[0037] In another preferred embodiment, the self-cleaving linker is selected from the following group: T2A, F2A, E2A, P2A, or a combination thereof.
[0038] In another preferred embodiment, the poly(A) is the polyadenylation signal of SV40 virus, and its nucleotide sequence is ≥95% identical to the nucleotide sequence shown in SEQ ID NO.:6, preferably ≥98%, and more preferably ≥99%.
[0039] In another preferred embodiment, the nucleotide sequence of the poly(A) is shown as SEQ ID NO.:6.
[0040] In another preferred embodiment, the length of each nucleotide linker sequence is 0-30 nt, preferably 1-15 nt.
[0041] In another preferred embodiment, the nucleotide sequence of the expression cassette is selected from the following group:
[0042] (a) the nucleotide sequence shown in SEQ ID NO:7;
[0043] (b) a nucleotide sequence having a sequence identity of ≥95% (preferably ≥98%, more preferably ≥99%) to the nucleotide sequence shown in SEQ ID NO: 7; and
[0044] (c) a nucleotide sequence complementary to the nucleotide sequence described in (a) or (b).
[0045] In another preferred embodiment, the nucleotide sequence includes a DNA sequence, a cDNA sequence, or an mRNA sequence.
[0046] In another preferred embodiment, the nucleotide sequence includes a single-stranded sequence and a double-stranded sequence.
[0047] The second aspect of the present invention provides a vector, wherein the vector comprises the expression cassette as described in the first aspect of the present invention.
[0048] In another preferred embodiment, the vector comprises one or more promoters, which are operably connected to the nucleic acid sequence, enhancer, intron, transcription termination signal, polyadenylation sequence, replication origin, selective marker, nucleic acid restriction site, and / or homologous recombination site.
[0049] In another preferred embodiment, the vector includes a plasmid or a viral vector.
[0050] In another preferred embodiment, the vector is selected from the following group: a lentiviral vector, an adenoviral vector, an adeno-associated viral vector (AAV), a DNA viral vector, a retroviral vector, or a combination thereof.
[0051] In another preferred embodiment, the vector is an adeno-associated virus AAV vector.
[0052] In another preferred embodiment, the vector is an AAV vector containing or inserted with nucleotide sequences encoding the heavy chain and light chain of the IgE antibody.
[0053] In another preferred embodiment, the vector is used to express the heavy chain and light chain of IgE antibody.
[0054] The third aspect of the present invention provides an adeno-associated viral vector, which contains the expression cassette described in the first aspect of the present invention.
[0055] In another preferred embodiment, the adeno-associated virus is AAV6 or AAV8.
[0056] In another preferred embodiment, the adeno-associated virus vector is used to treat allergic diseases.
[0057] In another preferred embodiment, the allergic disease is selected from the group consisting of allergic asthma, chronic spontaneous urticaria, or a combination thereof.
[0058] In another preferred embodiment, the adeno-associated virus vector has a structure of formula III:
[0059] A1-Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-A2 (Formula III)
[0060] in,
[0061] Each "-" is independently a bond or a nucleotide linking sequence;
[0062] A1 is the L-ITR sequence;
[0063] Z1 is the promoter;
[0064] Z2 is an optional first signal peptide coding sequence;
[0065] Z3 is an optional heavy chain coding sequence of an IgE antibody;
[0066] Z4 is the Furin cleavage site;
[0067] Z5 is the coding sequence of the self-splicing linker;
[0068] Z6 is an optional second signal peptide coding sequence; and
[0069] Z7 is the IgE antibody light chain coding sequence;
[0070] Z8 is an optional woodchuck hepatitis virus regulatory element WPRE element;
[0071] Z9 is an optional polyadenylation signal (polyA);
[0072] A2 is the R-ITR sequence.
[0073] In another preferred embodiment, the adeno-associated virus vector has a structure of Formula IV:
[0074] A1-Z1-Z2-Z3-Z4'-Z6-Z7-Z8-Z9-A2 (Formula IV)
[0075] in,
[0076] Each "-" is independently a bond or a nucleotide linking sequence;
[0077] A1, Z1, Z2, Z3, Z6, Z7, Z8, Z9, and A2 are defined as above, and Z4' is an IRES element.
[0078] In another preferred example, the L-ITR nucleotide sequence is shown as SEQ ID NO.:8.
[0079] In another preferred example, the R-ITR nucleotide sequence is shown as SEQ ID NO.:9.
[0080] In another preferred example, the sequence of the adeno-associated virus backbone vector comprises the sequence shown in SEQ ID NO.: 10 (ie, the nucleotide sequence of the vector without the target gene inserted).
[0081] In another preferred embodiment, the sequence of the adeno-associated virus vector is as shown in SEQ ID NO.: 11 (ie, the nucleotide sequence of the vector after the target gene is inserted).
[0082] The fourth aspect of the present invention provides a host cell comprising the vector as described in the second aspect of the present invention or the adeno-associated virus vector as described in the third aspect of the present invention, or an exogenous expression cassette as described in the first aspect of the present invention integrated into its chromosome.
[0083] In another preferred embodiment, the host cell is a mammalian cell, and the mammal includes human and non-human mammals.
[0084] In another preferred embodiment, the host cell is selected from the following group: 293T cells, 293 cells, or a combination thereof.
[0085] The fifth aspect of the present invention provides a use of the vector described in the second aspect of the present invention, the adeno-associated virus vector described in the third aspect of the present invention, or the host cell described in the fourth aspect of the present invention for preparing a preparation or composition for treating allergic diseases.
[0086] In another preferred embodiment, the allergic disease is selected from the group consisting of allergic asthma, chronic spontaneous urticaria, or a combination thereof.
[0087] The sixth aspect of the present invention provides a pharmaceutical preparation, which contains (a) the vector described in the second aspect of the present invention or the adeno-associated virus vector described in the third aspect of the present invention or the host cell described in the fourth aspect of the present invention, and (b) a pharmaceutically acceptable carrier or excipient.
[0088] In another preferred embodiment, the dosage form of the pharmaceutical preparation is selected from the following group: a lyophilized preparation, a liquid preparation, or a combination thereof.
[0089] In another preferred embodiment, the content of the carrier in the pharmaceutical preparation is 1×10 9 -1×10 16 Viruses / ml, preferably 1×10 12 -1×10 14 viruses / ml.
[0090] In another preferred embodiment, the pharmaceutical preparation is used to treat allergic diseases.
[0091] In another preferred embodiment, the allergic disease is selected from the group consisting of allergic asthma, chronic spontaneous urticaria, or a combination thereof.
[0092] In another preferred embodiment, the pharmaceutical preparation can be used alone or in combination for the treatment of allergic diseases.
[0093] In another preferred embodiment, the combined use includes: combined use with other drugs for treating allergic diseases.
[0094] The seventh aspect of the present invention provides a treatment method, which comprises administering the vector described in the second aspect of the present invention, the adeno-associated virus vector described in the third aspect of the present invention, or the host cell described in the fourth aspect of the present invention to a subject in need.
[0095] In another preferred embodiment, the subject in need includes humans and non-human mammals.
[0096] In another preferred embodiment, the non-human mammals include rodents and primates, preferably mice, rats, rabbits, and monkeys.
[0097] In another preferred embodiment, the administration dose of the vector described in the second aspect of the present invention, the adeno-associated virus vector described in the third aspect of the present invention, or the host cell described in the fourth aspect of the present invention is 1×10 12 -1×10 14 / kg body weight, preferably 5×10 12 -5×10 13 / kg body weight.
[0098] In another preferred embodiment, the administration frequency of the vector described in the second aspect of the present invention, the adeno-associated virus vector described in the third aspect of the present invention, or the host cell described in the fourth aspect of the present invention is a single treatment.
[0099] The eighth aspect of the present invention provides a method for preparing a recombinant adeno-associated virus vector, comprising culturing the host cell described in the fourth aspect of the present invention, thereby obtaining the recombinant adeno-associated virus vector.
[0100] A ninth aspect of the present invention provides a medicine kit, comprising:
[0101] (i) a first container, and an active ingredient (a) in the first container, wherein the active ingredient (a) is the vector described in the second aspect of the present invention, the adeno-associated virus vector described in the third aspect of the present invention, the host cell described in the fourth aspect of the present invention, or the pharmaceutical preparation described in the sixth aspect of the present invention;
[0102] (ii) an optional second container, and an active ingredient (b) in the second container, wherein the active ingredient (b) is other drugs for treating allergic diseases or their active ingredients.
[0103] In another preferred embodiment, the kit further comprises instructions for administering the active ingredients (a) and (b) to treat allergic diseases.
[0104] In another preferred embodiment, the first container and the second container are the same or different containers.
[0105] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0106] Figure 1 Ligelizumab-pUC plasmid electrophoresis is shown.
[0107] Figure 2 Ligel izumab-pUC plasmid restriction electrophoresis is shown.
[0108] Figure 3 The restriction electrophoresis of pAAV-CBH-MCS plasmid is shown.
[0109] Figure 4 The electrophoresis of bacterial solution PCR identification is shown.
[0110] Figure 5 The pAAV-CBH-MCS plasmid map of the present invention is shown.
[0111] Figure 6 The design of the expression cassette of the nucleic acid construct expressing Ligelizumab is shown.
[0112] Figure 7 A shows the design of the nucleic acid construct (adeno-associated virus vector) expressing Ligel izumab.
[0113] Figure 7 B shows a map of the nucleic acid construct expressing Ligel izumab.
[0114] Figure 8 The results of Western Blot detection of ligelizumab expression after cells were transduced with adeno-associated virus expressing ligelizumab.
[0115] Fig. 9 The binding of purified ligelizumab to IgE is shown.
[0116] Fig.10 The figure shows the trend of the antibody concentration in the serum of BALB / c mice after they were injected with adeno-associated virus expressing l igelizumab.
[0117] Fig.11 The number of total leukocytes in bronchoalveolar lavage fluid of mice is shown.
[0118] Fig.12 The number of eosinophils in bronchoalveolar lavage fluid of mice is shown.
[0119] Fig.13 The pKL-lenti-kan-CBH-WPRE plasmid map is shown.
[0120] Fig.14 A lentiviral gene therapy vector for the human IgE neutralizing antibody ligelizumab is shown.
[0121] Fig.15 The expression of ligelizumab in the supernatant after the lentivirus-transduced cells were detected by SDS-PAGE, wherein: 1, supernatant of cells expressing ligelizumab; 2, flow-through of cell supernatant; 3, 5ug of purified ligelizumab (the sample was added to a loading buffer without β-mercaptoethanol); 4, 5ug of purified ligelizumab (the sample was added to a loading buffer containing β-mercaptoethanol). DETAILED DESCRIPTION
[0122] After extensive and in-depth research and a large amount of screening, the inventors have developed for the first time a gene therapy adeno-associated virus vector that can effectively treat allergic diseases. Specifically, the present invention provides an expression cassette for gene therapy of allergic diseases, which can be used for gene therapy of allergic diseases such as chronic spontaneous urticaria and allergic asthma. The expression cassette is used to produce adeno-associated virus gene therapy vectors for gene therapy of the above-mentioned allergic diseases with higher efficiency and lower cost. Experimental results show that the gene expression framework of the adeno-associated virus vector of the present invention can achieve a high level of expression of the target gene, and can be used to treat allergic diseases such as allergic asthma and chronic spontaneous urticaria. On this basis, the inventors have completed the present invention.
[0123] the term
[0124] In order to more easily understand the present disclosure, some terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms should have the meaning given below. Other definitions are set forth throughout the application.
[0125] The term "about" can refer to a value or composition that is within an acceptable error range for a particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined. For example, as used herein, the expression "about 100" includes all values between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0126] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".
[0127] Sequence identity is determined by comparing two aligned sequences along a predetermined comparison window (which can be 50%, 60%, 70%, 80%, 90%, 95% or 100% of the length of the reference nucleotide sequence or protein) and determining the number of positions at which identical residues occur. Typically, this is expressed as a percentage. The measurement of sequence identity of nucleotide sequences is a method well known to those skilled in the art.
[0128] As used herein, the term "subject", "subject in need" refers to any mammal or non-mammal. Mammals include, but are not limited to, humans, vertebrates such as rodents, non-human primates, cows, horses, dogs, cats, pigs, sheep, goats.
[0129] Ligelizumab
[0130] Ligelizumab is another fully humanized monoclonal IgG1 antibody targeting human IgE. It binds to the Cε3 domain of IgE. Ligelizumab has a strong and lasting inhibitory effect on free IgE on the surface of mast cells and basophils, which helps to better block the allergic cascade reaction and improve the clinical effect of treating asthma. It includes the heavy chain and light chain of Ligelizumab (also known as Ligelizumab).
[0131] Furin cleavage site
[0132] In the present invention, the furin cleavage site is an amino acid site that can be cleaved by furin protease, a typical furin cleavage site Arg-X-(Arg / Lys)-Arg, and the furin protease cleaves the protein downstream of the typical furin cleavage site. Furin-2A-mediated vector cleavage is very effective, and its advantage is that the self-cleavage efficiency is high, ensuring the same light and heavy chain expression amount of the same open reading frame.
[0133] IRES
[0134] In the present invention, "IRES linker" and "IRES" are used interchangeably, and both are referred to as internal ribosome entry site sequences (Internal ribosome entry site, IRES). It is located at the 5 end of the gene and is a short RNA sequence (about 150-250bp). This type of RNA sequence can fold into a structure similar to the initiator tRNA, thereby mediating ribosomal RNA binding and initiating protein translation. The IRES element has the function of independently recruiting ribosomes without relying on the cap structure, and can then initiate the translation of downstream genes.
[0135] Nucleic acid coding sequence
[0136] The present invention provides an AAV viral vector expressing the heavy chain and light chain of an anti-IgE antibody.
[0137] Exemplarily, the present invention provides an AAV viral vector expressing the heavy chain and light chain of Ligelizumab, the nucleotide sequence of which is shown in SEQ ID NO.: 11. In another preferred embodiment, the nucleotide sequence has ≥95% identity with the nucleotide sequence shown in SEQ ID NO.: 11, preferably ≥98%, and more preferably ≥99%.
[0138] The polynucleotide of the present invention may be in the form of DNA or RNA. In another preferred embodiment, the nucleotide is DNA. The DNA form includes cDNA, genomic DNA or artificially synthesized DNA. DNA may be single-stranded or double-stranded. DNA may be a coding strand or a non-coding strand. The AAV viral vector of the present invention expresses the heavy chain and light chain of Ligelizumab, the amino acid sequence of the heavy chain is shown in SEQ ID NO.:3, the nucleotide sequence is shown in SEQ ID NO.:2, the amino acid sequence of the light chain is shown in SEQ ID NO.5, the nucleotide sequence is shown in SEQ ID NO.4, and the structure is shown in Figure 6 shown.
[0139] The nucleic acid sequence can be DNA, RNA, cDNA or PNA. The nucleic acid sequence can be genomic, recombinant or synthetic. The nucleic acid sequence can be isolated or purified. The nucleic acid sequence can be single-stranded or double-stranded. Preferably, the nucleic acid sequence will encode the heavy chain and light chain of Ligelizumab as described herein. The nucleic acid sequence can be derived by cloning, for example, using standard molecular cloning techniques including restriction enzyme cutting, connection, gel electrophoresis, such as described in Sambrook et al. Molecular Cloning: A laboratory manual, Cold Spring Harbour Laboratory Press). The nucleic acid sequence can be isolated, for example, using PCR technology to separate. Separation means separating the nucleic acid sequence from any impurities and from other nucleic acid sequences and / or proteins that are naturally found to be associated with the nucleic acid sequence in its source. Preferably, it will also be free of cell material, culture medium or other chemicals from the purification / production process. The nucleic acid sequence can be synthetic, for example, produced by direct chemical synthesis. The nucleic acid sequence can be provided as naked nucleic acid, or can be provided in combination with protein or lipid.
[0140] The full-length nucleotide sequence of the present invention or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. For PCR amplification, primers can be designed based on the disclosed relevant nucleotide sequence, especially the open reading frame sequence, and a commercially available cDNA library or a cDNA library prepared by conventional methods known to those skilled in the art is used as a template to amplify the relevant sequence. When the sequence is long, it is often necessary to perform two or more PCR amplifications, and then splice the fragments amplified each time together in the correct order. At present, the DNA sequence encoding the polypeptide of the present invention (or its fragment, or its derivative) can be obtained completely by chemical synthesis. The DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art.
[0141] The present invention also relates to vectors comprising the polynucleotides of the present invention, and host cells produced by genetic engineering using the vectors or polypeptide coding sequences of the present invention. The above polynucleotides, vectors or host cells may be isolated.
[0142] As used herein, "isolated" means that a substance is separated from its original environment (if it is a natural substance, the original environment is the natural environment). For example, polynucleotides and polypeptides in their natural state in living cells are not isolated and purified, but the same polynucleotides or polypeptides are isolated and purified if they are separated from other substances that exist with them in their natural state.
[0143] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, then transferring it into cells, and then isolating the relevant sequence from the propagated host cells by conventional methods.
[0144] In addition, artificial synthesis methods can also be used to synthesize related sequences, especially when the fragment length is shorter. Usually, a long fragment of sequence can be obtained by synthesizing multiple small fragments first and then connecting them.
[0145] The method of using PCR technology to amplify DNA / RNA is preferably used to obtain the gene of the present invention. The primers used for PCR can be appropriately selected according to the sequence information of the present invention disclosed herein, and can be synthesized by conventional methods. The DNA / RNA fragments amplified can be separated and purified by conventional methods such as by gel electrophoresis.
[0146] The present invention also relates to a vector comprising the polynucleotide of the present invention, a host cell produced by genetic engineering using the vector or protein coding sequence of the present invention, and a method of expressing the heavy chain and light chain of Ligelizumab using the host cell by recombinant technology.
[0147] The polynucleotide sequence of the present invention can be used to obtain a host cell (such as a mammalian cell) expressing the heavy chain and light chain of the ligelizumab of the present invention by conventional recombinant DNA technology. Generally, the process comprises the steps of: transducing the expression cassette of the first aspect of the present invention, the vector of the second aspect of the present invention, or the adeno-associated virus vector of the third aspect of the present invention into the host cell.
[0148] Methods well known to those skilled in the art can be used to construct expression vectors containing the coding DNA sequence of the polypeptide of the present invention and appropriate transcription / translation control signals. These methods include in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology, etc. The DNA sequence can be effectively linked to an appropriate promoter in the expression vector to guide mRNA synthesis. The expression vector also includes a ribosome binding site for translation initiation and a transcription terminator.
[0149] In addition, the expression vector preferably contains one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance and green fluorescent protein (GFP) for eukaryotic cell culture, or tetracycline or ampicillin resistance for Escherichia coli.
[0150] A vector containing the above-mentioned appropriate DNA sequence and an appropriate promoter or control sequence can be used to transform an appropriate host cell to enable it to express the polypeptide.
[0151] The host cell can be a prokaryotic cell, a lower eukaryotic cell, or a higher eukaryotic cell, such as a mammalian cell (including human and non-human mammals). Representative examples include: animal cells of CHO, NS0, COS7, or 293 cells, etc. In a preferred embodiment of the present invention, 293T cells or 293 cells are selected as host cells.
[0152] Transformation of host cells with recombinant DNA can be carried out using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA can be harvested after the exponential growth phase and treated with the CaCl2 method, the steps used are well known in the art. Another method is to use MgCl2. If necessary, transformation can also be carried out using electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be selected: calcium phosphate coprecipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
[0153] The obtained transformant can be cultured by conventional methods to express the protein encoded by the gene of the present invention. Depending on the host cell used, the culture medium used in the culture can be selected from various conventional culture media. Culture is carried out under conditions suitable for the growth of the host cells. After the host cells grow to an appropriate cell density, the promoter selected is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
[0154] The polypeptide in the above method can be expressed in the cell, on the cell membrane, or secreted outside the cell. If necessary, the protein can be separated and purified by various separation methods using its physical, chemical and other properties. These methods are well known to those skilled in the art. Examples of these methods include but are not limited to: conventional renaturation treatment, treatment with a protein precipitant (salting out method), centrifugation, osmotic sterilization, ultra-treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography techniques and combinations of these methods.
[0155] Adeno-associated virus
[0156] Adeno-associated virus (AAV) has attracted widespread attention for its smaller size, non-pathogenicity, and ability to transfect both dividing and non-dividing cells compared to other viral vectors.
[0157] Adeno-associated virus (AAV), also known as adeno-associated virus, belongs to the genus Dependinovirus of the family Parvoviridae. It is the simplest type of single-stranded DNA defective virus discovered so far, and requires a helper virus (usually adenovirus) to participate in replication. It encodes the cap and rep genes in the inverted repeat sequences (ITR) at both ends. ITRs play a decisive role in the replication and packaging of the virus. The cap gene encodes the viral capsid protein, and the rep gene is involved in the replication and integration of the virus. AAV can infect a variety of cells.
[0158] Recombinant adeno-associated virus vector (rAAV) is derived from non-pathogenic wild-type adeno-associated virus. Due to its good safety, wide range of host cells (dividing and non-dividing cells), low immunogenicity, and long-term expression of foreign genes in vivo, it is regarded as one of the most promising gene transfer vectors and has been widely used in gene therapy and vaccine research worldwide. After more than 10 years of research, the biological characteristics of recombinant adeno-associated virus have been deeply understood, especially its application effects in various cells, tissues and in vivo experiments have been accumulated. In medical research, rAAV has been used in the study of gene therapy for a variety of diseases (including in vivo and in vitro experiments); at the same time, as a characteristic gene transfer vector, it is also widely used in gene function research, construction of disease models, preparation of gene knockout mice, etc.
[0159] In a preferred embodiment of the present invention, the vector is a recombinant AAV vector. AAV is a relatively small DNA virus that can be integrated into the genome of the cells they infect in a stable and site-specific manner. They can infect a large series of cells without any effect on cell growth, morphology or differentiation, and they do not seem to be involved in human pathology. The AAV genome has been cloned, sequenced and characterized. AAV contains an inverted terminal repeat (ITR) region of about 145 bases at each end, which serves as the origin of viral replication. The rest of the genome is divided into two important regions with encapsidation function: the left part of the genome containing the rep gene involved in viral replication and viral gene expression; and the right part of the genome containing the cap gene encoding the viral capsid protein.
[0160] AAV vectors can be prepared using standard methods in the art. Any serotype of adeno-associated virus is suitable. Methods for purifying vectors can be found in, for example, U.S. Patent Nos. 6,566,118, 6,989,264, and 6,995,006, the disclosures of which are incorporated herein by reference in their entirety. The preparation of hybrid vectors is described, for example, in PCT Application No. PCT / US2005 / 027091, the disclosures of which are incorporated herein by reference in their entirety. The use of vectors derived from AAV for transporting genes in vitro and in vivo has been described (see, for example, International Patent Application Publication Nos. WO91 / 18088 and WO93 / 09239; U.S. Patent Nos. 4,797,368, 6,596,535, and 5,139,941, and European Patent No. 0488528, all of which are incorporated herein by reference in their entirety). These patent publications describe various AAV-derived constructs in which the rep and / or cap genes are deleted and replaced by the gene of interest, and the use of these constructs to transport the gene of interest in vitro (into cultured cells) or in vivo (directly into an organism). Replication-deficient recombinant AAV can be prepared by co-transfecting the following plasmids into a cell line infected with a human helper virus (e.g., adenovirus): a plasmid containing the nucleic acid sequence of interest flanked by two AAV inverted terminal repeat (ITR) regions, and a plasmid carrying the AAV encapsidation genes (rep and cap genes). The resulting AAV recombinants are then purified by standard techniques.
[0161] In some embodiments, the recombinant vector is encapsidated into a viral particle (e.g., AAV viral particles including, but not limited to, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, and AAV16). Thus, the present disclosure includes recombinant viral particles (recombinant because they contain a recombinant polynucleotide) containing any of the vectors described herein. Methods for producing such particles are known in the art and are described in U.S. Pat. No. 6,596,535.
[0162] Expression vectors and host cells
[0163] The present invention also provides an expression vector for expressing the heavy chain and light chain of Ligelizumab (also known as Ligelizumab).
[0164] Given the sequence information, a skilled artisan can use available cloning techniques to generate nucleic acid sequences or vectors suitable for transduction into cells.
[0165] Preferably, the nucleic acid sequence of the heavy chain and light chain of Ligelizumab (also known as Ligelizumab) encoding ligol group monoclonal antibody is provided as a vector, preferably an expression vector. Preferably, it can be provided as a gene therapy vector preferably suitable for transduction and expression in 293T cells. The vector can be viral or non-viral (e.g., plasmid). Viral vectors include those derived from the following viral vectors: adenovirus, adeno-associated virus (AAV) including a mutated form, retrovirus, slow virus, herpes virus, vaccinia virus, MMLV, GaLV, simian immunodeficiency virus (SIV), HIV, poxvirus and SV40. Preferably, the viral vector is replication defective, although it is envisioned that it can be replication deficient, can be replicated or conditionally replicated. The viral vector can usually maintain an extrachromosomal state without integration into the genome of the 293T cell. The preferred viral vector for introducing the nucleic acid sequence of the heavy and light chains of Ligelizumab (also known as Ligelizumab) encoding to 293T cells is an AAV vector, such as a self-complementary adeno-associated virus (scAAV). Selective targeting can be achieved using a specific AAV serotype (AAV serotype 2 to AAV serotype 12) or a modified version of any of these serotypes (including AAV 4YF and AAV 7m8 vectors).
[0166] In another preferred embodiment, the adeno-associated virus used in the present invention is AAV8, and preferably, the adeno-associated virus is single-stranded AAV8.
[0167] The viral vector can be modified to delete any non-essential sequence. For example, in AAV, the virus can be modified to delete all or part of the IX gene, Ela and / or Elb gene. For wild-type AAV, without the presence of a helper virus such as adenovirus, replication is very inefficient. For recombinant adeno-associated viruses, preferably, replication genes and capsid genes are provided in trans (in pRep / Cap plasmids), and only the 2ITR of the AAV genome is retained and packaged into the virion, while the required adenoviral genes are provided by adenovirus or another plasmid. Similar modifications can also be made to lentiviral vectors.
[0168] Viral vectors have the ability to enter cells. However, non-viral vectors such as plasmids can be compounded with agents to facilitate the uptake of viral vectors by target cells. Such agents include polycationic agents. Alternatively, delivery systems such as liposome-based delivery systems can be used. The carrier used in the present invention is preferably suitable for use in vivo or in vitro, and is preferably suitable for use in humans.
[0169] The vector will preferably contain one or more regulatory sequences to direct the expression of the nucleic acid sequence in the retinal target cells. Regulatory sequences may include promoters, introns, enhancers, transcription termination signals, polyadenylation sequences, replication origins, nucleic acid restriction sites, and homologous recombination sites operably linked to the nucleic acid sequence. The vector may also include a selective marker, for example to determine expression of the vector in a growth system (e.g., bacterial cells) or in retinal target cells.
[0170] "Operably linked" means that a nucleic acid sequence is functionally related to a sequence to which it is operably linked, such that they are linked in a manner such that they affect the expression or function of each other. For example, a nucleic acid sequence operably linked to a promoter will have an expression pattern affected by the promoter.
[0171] The promoter mediates the expression of the nucleic acid sequence connected thereto. The promoter may be constitutive or inducible. The promoter may direct ubiquitous expression in inner retinal cells, or neuron-specific expression. In the latter case, the promoter may direct cell type-specific expression, such as to optic ganglion cells. Suitable promoters will be known to those skilled in the art. For example, suitable promoters may be selected from the group consisting of: L7, thy-1, recovery protein, calcium binding protein, human CMV, GAD-67, chicken beta actin, hSyn, Grm6, Grm6 enhancer SV40 fusion protein. Targeting may be achieved using a cell-specific promoter, such as Grm6-SV40 for selective targeting to optic nerve cells. The Grm6 promoter is a fusion of a 200 base pair enhancer sequence of the Grm6 gene and a SV40 eukaryotic promoter, and the Grm6 gene encodes a metabotropic glutamate receptor mGluR6 specific to optic nerve cells. The preferred sources of the Grm6 gene are mice and humans. Ubiquitous expression can be achieved using a pan-neuronal promoter, examples of which are known and available in the art. One such example is CAG. The CAG promoter is a fusion of the CMV early enhancer and the chicken beta actin promoter.
[0172] An example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence that can drive any polynucleotide sequence operably connected thereto to express at a high level. Another example of a suitable promoter is elongation growth factor-1α (EF-1α). However, other constitutive promoter sequences may also be used, including but not limited to simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukemia virus promoter, Epstein-Barr (Epstein-Barr) virus immediate early promoter, Rous sarcoma virus promoter, and human gene promoters, such as but not limited to actin promoter, myosin promoter, heme promoter, and creatine kinase promoter. Further, the present invention should not be limited to the application of constitutive promoters. Inducible promoters are also considered to be part of the present invention. The use of an inducible promoter provides a molecular switch that can turn on the expression of a polynucleotide sequence operably linked to an inducible promoter when such expression is desired, or turn off expression when expression is undesirable. Examples of inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.
[0173] An example of a suitable promoter is the CBH promoter.
[0174] Many expression vectors can be used to express the heavy chain and light chain of Ligelizumab (also known as Ligelizumab) in mammalian cells (preferably human, more preferably human 293T cells). The present invention preferably uses adeno-associated virus as an expression vector.
[0175] The present invention also provides a method for constructing a recombinant adeno-associated virus vector comprising the heavy chain and light chain coding sequences of ligel izumab (also known as ligalizumab). The method can quickly and easily construct a recombinant adeno-associated virus vector carrying the heavy chain and light chain coding sequences of ligalizumab (also known as ligalizumab), and package it to obtain a complex defective adeno-associated virus vector.
[0176] In another preferred embodiment, the sequence of the adeno-associated virus vector carrying the heavy chain and light chain coding sequences of Ligel izumab (also known as Ligelizumab) of the present invention is as shown in SEQ ID NO.:11.
[0177] Gene therapy vectors
[0178] The gene therapy vector in the present invention is a viral expression vector. According to the present invention, the viral expression vector is an adeno-associated virus (AAV) vector, which is better suited for efficient transduction in tissues of interest. During transfection, AAV only causes a slight immune response (if any) in the host. In a preferred embodiment of the present invention, the gene therapy vector is an AAV serotype 8 vector.
[0179] At present, recombinant adeno-associated virus (rAAV) is one of the important viral vectors in the field of gene therapy. Its safety and effectiveness have been verified in many clinical trials and have broad application prospects. In order to develop an ideal gene therapy product for the treatment of allergic diseases, we have selected a recombinant adeno-associated virus (rAAV) vector with a wide host range, the ability to infect dividing cells and non-dividing cells, high virus titer, strong specificity, low toxicity and immunogenicity, no integration into chromosomes, and the ability to express exogenous genes for a long time. This patent uses rAAV8 vectors to carry the ligelizumab encoding gene, which is injected intramuscularly into IgE / FcεRI double humanized BALB / c asthma model mice, which can significantly reduce the proportion of eosinophils in total white blood cells in the alveolar lavage fluid, and reduce the secretion of Th2 cytokines, thereby alleviating asthma symptoms. The present invention provides a gene therapy drug for allergic diseases, and no related reports have been seen at home and abroad so far.
[0180] The AAV vector of the present invention is a single-stranded AAV, and recombinant viral vectors can be produced according to standard techniques. For example, recombinant adeno-associated viral vectors can be packaged in human 293T cells (which provide trans-E1A and E1B properties) to achieve 10 10 -10 13 The titer of the virus can be within the range of 100 virus particles / mL. Before in vivo use, the viral vector can be purified by affinity purification and purified by subsequent filtration. Purification reduces potential harmful effects in the main body of the drug delivery vehicle. The administered virus is substantially free of wild-type virus and replicable virus. The purity of the virus can be demonstrated by a suitable method, such as sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by silver staining, or HPLC.
[0181] A suitable dose of AAV for use in humans is about 1 × 10 12 -1×10 14 vg / kg range.
[0182] Gene therapy vectors can be administered by injection.
[0183] The present invention also provides a host cell for packaging adeno-associated viruses containing Ligelizumab heavy chain and light chain genes. Preferably, the host cell is a mammalian cell (preferably a human, more preferably a human 293T cell), and then the adeno-associated virus containing Ligelizumab heavy chain and light chain genes is used to infect cells or animals to express Ligelizumab antibodies in vivo and in vitro.
[0184] In a preferred embodiment, the present invention provides an adeno-associated virus vector for gene therapy of allergic diseases. Experimental results show that the gene expression framework of the adeno-associated virus vector can achieve high-level expression of the target gene, and the gene sequence construct can be used to treat allergic diseases such as allergic asthma and chronic spontaneous urticaria. The following are the cis-acting elements, replication initiation sites, and polyadenylation signals used in this vector:
[0185] 1. The cis-acting element CBH (CMV Enhancer+chickenβ-actin promoter+hybridintron) is located upstream of the antibody gene sequence and is involved in the expression regulation of the antibody gene sequence. Experimental results show that this element can effectively increase gene expression.
[0186] 2. SV40 polyadenylation signal Polyadenylation is a mechanism that promotes the covalent attachment of polyadenylic acid to messenger RNA (mRNA) molecules during protein biosynthesis. The polyadenylic acid tail (or poly A tail) protects mRNA from exonuclease attack and is important for transcription termination, nuclear export of mRNA, and subsequent translation.
[0187] 3.pBR322_origin is the replication region sequence of plasmid pBR322. In Escherichia coli, the replication of the plasmid starts from this site.
[0188] 4. Ligelizumab codon optimization. Codon optimization is an important step in optimizing gene expression, which involves multiple aspects such as codon usage preference, rare codons, mRNA secondary structure, GC content distribution, and splicing sites.
[0189] The experimental data of the present invention show that the adeno-associated virus vector pAAV-CBH-ligelizumab can be used for highly efficient gene therapy of allergic diseases such as allergic asthma and chronic spontaneous urticaria.
[0190] Formulations and compositions
[0191] The present invention provides a preparation or composition, which contains (a) the vector described in the second aspect of the present invention or the adeno-associated virus vector described in the third aspect of the present invention, and (b) a pharmaceutically acceptable carrier or excipient.
[0192] In another preferred embodiment, the pharmaceutical preparation is used to treat allergic diseases.
[0193] For the convenience of clinical application, the pharmaceutical composition of the present invention can be contained in an injection device (such as an injection needle), and the injection device can contain a single dose of the pharmaceutical composition. The injection device can be contained in a medicine box for easy storage and use. During transportation, the small container containing the drug suspension needs to be placed in dry ice. It should be stored in a -80°C refrigerator at ordinary times.
[0194] The medicine box or test kit of the present invention may also include instructions for use to facilitate those skilled in the art to use it in the correct manner.
[0195] The "active ingredient" in the pharmaceutical composition of the present invention refers to the vector described in the present invention, such as a viral vector (including an adeno-associated viral vector). The "active ingredient", preparation and / or composition described in the present invention can be used to treat eye diseases. "Safe and effective amount" means: the amount of the active ingredient is sufficient to significantly improve the condition or symptoms without causing serious side effects. "Pharmaceutically acceptable carrier or excipient" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the active ingredient of the present invention and with each other without significantly reducing the efficacy of the active ingredient.
[0196] The composition may be a liquid or solid, such as a powder, gel or paste. Preferably, the composition is a liquid, preferably an injectable liquid. Suitable excipients will be known to those skilled in the art.
[0197] In the present invention, the carrier is provided as an injectable liquid. Preferably, the injectable liquid is provided as a capsule or a syringe.
[0198] Examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0199] The composition may comprise a physiologically acceptable sterile aqueous or anhydrous solution, dispersion, suspension or emulsion, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0200] The nucleic acid or fusion nucleic acid encoding the heavy chain and light chain of Ligelizumab (also known as Ligelizumab) provided by the present invention can produce the heavy chain and light chain of Ligelizumab (also known as Ligelizumab) in vitro or in vivo, and the preparation containing the heavy chain and light chain of Ligelizumab (also known as Ligelizumab) can be used to prepare drugs for treating allergic diseases.
[0201] Treatment
[0202] The present invention provides a method for treating an allergic disease, the method comprising introducing into the body a vector comprising a nucleic acid sequence encoding the heavy chain and light chain of Ligelizumab (also known as Ligelizumab). The method may comprise administering the nucleic acid vector into the body.
[0203] The present invention provides a nucleic acid vector for use in a method for treating an allergic disease, the nucleic acid vector comprising a nucleic acid sequence encoding the heavy chain and light chain of Ligelizumab (also known as Ligelizumab). The composition of the present invention can be administered alone or in combination with other therapeutic drugs (e.g., formulated in the same pharmaceutical composition).
[0204] As used herein, treating a disease means administering a nucleic acid or vector as described herein to improve or alleviate one or more symptoms of the disease.
[0205] The method of the present invention comprises introducing nucleic acid sequences encoding the heavy and light chains of Ligelizumab (also known as Ligelizumab) into the body. Preferably, the method comprises contacting a cell with a vector (preferably a virus, more preferably an adeno-associated virus) comprising nucleic acid sequences encoding the heavy and light chains of Ligelizumab (also known as Ligelizumab). Preferably, the cell is an animal or a human. When the nucleic acid sequence is provided in multiple (two or more) doses, the doses may be separated by suitable time intervals, for example 30 seconds to several hours or 1 day or more days.
[0206] Each dose may contain an effective amount of nucleic acid sequence or viral vector. The effective dose of nucleic acid sequence or viral vector may be 1×10 12 -1×10 14 The range of vg / kg virus.
[0207] Pharmaceutical composition and medicine kit
[0208] As used herein, the term "comprising" includes "containing," "consisting essentially of," and "consisting of.
[0209] As used herein, the term "consisting essentially of..." means that the pharmaceutical composition, in addition to the effective active ingredients or auxiliary ingredients, may contain minor ingredients and / or impurities in small amounts that do not affect the effective ingredients.
[0210] For the convenience of clinical application, the pharmaceutical composition of the present invention can be contained in an injection device (such as an injection needle), and the injection device can contain a single dose of the pharmaceutical composition. The injection device can be contained in a medicine box for easy storage and use. During transportation, the small container containing the drug suspension needs to be placed in dry ice. It should be stored in a -80°C refrigerator at ordinary times.
[0211] The medicine box or test kit of the present invention may also include instructions for use to facilitate those skilled in the art to use it in the correct manner.
[0212] As used herein, the term "effective amount" or "effective dose" refers to an amount that can produce a function or activity on humans and / or animals and can be accepted by humans and / or animals.
[0213] The effective amount of the active ingredient of the present invention may vary depending on the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated, the patient's weight, the patient's immune status, the route of administration, etc. For example, several divided doses may be administered daily, or the dose may be reduced proportionally, depending on the urgency of the treatment situation.
[0214] As used herein, a "pharmaceutically acceptable" ingredient is a substance that is suitable for use in humans and / or mammals without excessive adverse side effects (eg, toxicity), ie, at a reasonable benefit / risk ratio.
[0215] The term "pharmaceutically acceptable carrier" refers to carriers used for the administration of therapeutic agents, including various excipients and diluents, that is, pharmaceutical carriers that are not essential active ingredients themselves and are not overly toxic after administration.
[0216] Suitable pharmaceutically acceptable carriers are well known to those of ordinary skill in the art. A full description of pharmaceutically acceptable carriers can be found in Remington's Pharmaceutical Sciences (Mack Pub. Co., NJ 1991); the pharmaceutically acceptable carrier in the composition may contain a liquid such as water, BBS (Balanced Salt Solution) phosphate buffer, Ringer solution, physiological saline, balanced salt solution, glycerol or sorbitol, etc.
[0217] In addition, these carriers may also contain auxiliary substances, such as lubricants, glidants, wetting agents or emulsifiers, pH buffer substances and stabilizers.
[0218] In an embodiment of the present invention, the pharmaceutical composition is in liquid dosage form; preferably an injection.
[0219] The pharmaceutical composition of the present invention can be used alone or in combination for the treatment of allergic diseases. The combined use includes: combined use with other drugs for the treatment of allergic diseases. Among them, the other drugs for the treatment of allergic diseases include: antihistamines, leukotriene receptor antagonists, β2-adrenergic receptor agonists and glucocorticoids.
[0220] In addition, the present invention has created a gene therapy construct for allergic diseases based on a recombinant adeno-associated virus vector. The heavy chain and light chain of Ligelizumab, a neutralizing antibody against IgE, were fused and expressed through F2A to form a simple and efficient expression framework. The experimental results showed that the expression framework achieved a high expression efficiency after delivery via the rAAV vector.
[0221] The object of the present invention is to provide a nucleic acid construct for gene therapy of allergy-related diseases, so as to solve the problems in the prior art.
[0222] To achieve the above object, the present invention provides a nucleic acid construct, which comprises nucleotides encoding Ligelizumab.
[0223] The present invention also provides an adeno-associated virus vector system, which comprises the nucleic acid construct and a helper plasmid.
[0224] The present invention also provides an adeno-associated virus, wherein the adeno-associated virus is formed by viral packaging of the nucleic acid construct.
[0225] The present invention also provides a cell line, which is the cell line required for packaging the adeno-associated virus.
[0226] The present invention also provides the use of the nucleic acid construct, adeno-associated virus, adeno-associated virus vector system, cell line, etc. in preparing products for preventing and treating asthma and other related allergic diseases.
[0227] As described above, the nucleic acid construct for gene therapy of allergic-related diseases of the present invention has the following beneficial effects: the present invention creates a nucleic acid construct containing a ligelizumab expression framework, which can be used to efficiently express active ligelizumab both in vivo and in vitro, which provides a therapeutic idea for gene therapy drugs for allergic diseases such as allergic asthma and chronic spontaneous urticaria. The construct of the present invention is delivered by a viral vector or a non-viral vector and can be used for gene therapy of allergic asthma-related diseases.
[0228] In addition, the present invention also prepares a nucleic acid construct, that is, the heavy chain and light chain of Ligelizumab monoclonal antibody are connected in series through a cleavable 2A peptide, and then subcloned into an rAAV expression vector. The construct includes, from 5' to 3', the following: the 5' inverted terminal repeat sequence (5'ITR) of AAV, a promoter, the heavy chain of the antibody (including a signal peptide), a F2A short peptide, the light chain of the antibody (including a signal peptide), WPRE, a polyadenylation signal (polyA), and the 3' inverted terminal repeat sequence (3'ITR) of AAV. Among them, the promoter can be CMV (GenBank: MN996867.1, 235-818), CBH (SEQ ID NO.: 1), EF1α (GenBank: KY447299.1, 529-1710), CAG (GenBank: KC152483.1, 200-1096), CAGG (GenBank: GU299216.1, 63-1664), CASI (GenBank: ON512571.1, 80-1104), desmin (GenBank: M63391.1, 2194-3233), TMCK (SEQ ID NO.: 12), MCK (SEQ ID NO.: 13), MHCK7 (SEQ ID NO.: 14), PGK (GenBank: JF313343.1, 683-1192), TTR (SEQ ID NO.: 15). The signal peptide can be any one of SAP signal peptide (SEQ ID NO.: 16), IHC signal peptide (SEQ ID NO.: 17), ILC signal peptide (SEQ ID NO.: 18), AP signal peptide (SEQ ID NO.: 19), CSP signal peptide (SEQ ID NO.: 20), IL2 signal peptide (SEQ ID NO.: 21), TPA signal peptide (SEQ ID NO.: 22), L1 signal peptide (SEQ ID NO.: 23), H7 signal peptide (SEQ ID NO.: 24). The 2A peptide connecting the heavy chain and the light chain is any one of T2A, F2A, E2A, and P2A. The construct is co-transfected with two other AAV packaging plasmids pAAV-RC and phelper into 293T cells to obtain an infectious rAAV vector. After purification, the viral vector can be used for intramuscular or intravenous injection into the patient's body to express Ligelizumab for a long time. The expressed antibody can neutralize the allergenic IgE in the patient's body, thereby playing a role in treating allergic diseases such as allergic asthma and chronic spontaneous urticaria. The capsid used to package AAV in the present invention can be derived from any one of AAV1, AAV2, AAV3, AAV4, AAV7, AAV8, AAV9, AAVrh.10, AAVDJ / 8, and AAV6.2FF.
[0229] The specific implementation method is to construct an antibody molecule and clone it into an rAAV vector. In 293T cells, it is packaged into the corresponding adeno-associated virus, and the 293T cells and differentiated muscle cell lines are infected with viruses of a certain biological titer. The antibody molecules produced in the cell supernatant are quantitatively and qualitatively detected, and ordinary BALB / c mice are injected intramuscularly with viruses of a certain biological titer to detect the expression of Ligelizumab. Finally, the adeno-associated virus is injected intramuscularly into IgE / FcεRI double humanized BALB / c asthma model mice to detect the proportion of eosinophils in the alveolar lavage fluid to the total leukocytes.
[0230] The main advantages of the present invention include:
[0231] (1) The present invention provides for the first time an adeno-associated virus vector for gene therapy that can effectively treat allergic diseases. Specifically, the present invention provides an expression cassette for gene therapy of allergic diseases, which can be used for gene therapy of allergic diseases such as chronic spontaneous urticaria and allergic asthma. The expression cassette is used to produce adeno-associated virus gene therapy vectors for gene therapy of the above-mentioned allergic diseases with higher efficiency and lower cost. Experimental results show that the gene expression framework of the adeno-associated virus vector of the present invention can achieve high levels of expression of the target gene, and can be used to treat allergic diseases such as allergic asthma and chronic spontaneous urticaria.
[0232] (2) The present invention is for in vivo production of antibodies. The traditional treatment method is to use genetic engineering technology to recombinantly express anti-IgE antibodies in vitro, and then administer them by subcutaneous injection to neutralize the allergenic IgE in the body and control symptoms. However, the half-life of antibodies in the body is short, and they need to be injected once a month, which is expensive and inconvenient for patients. The present invention constructs anti-IgE antibody molecules into rAAV vectors, and then packages them into infectious rAAV in vitro, and then delivers them to the patient's body, so that they can produce IgE antibodies in the body for a long time, thereby achieving a one-time administration and long-term effective effect.
[0233] (3) The present invention is a muscle tissue-specific expression vector. The viral vector packaged by the construct of the present invention can be targeted for expression in muscle. Since the rAAV viral vector does not integrate into the genome in cells but exists in the form of free bodies, it is very easy to lose the rAAV viral vector for cells that differentiate rapidly or divide vigorously, thereby losing the corresponding function. Muscle cells almost do not differentiate throughout life, and this characteristic is very suitable for the long-term continuous expression of rAAV gene therapy vectors, so as to exert long-term therapeutic functions.
[0234] (4) The present invention creates a nucleic acid construct containing a ligelizumab expression framework, which can be used to efficiently express active ligelizumab both in vivo and in vitro, providing a therapeutic approach for gene therapy drugs for allergic diseases such as allergic asthma and chronic spontaneous urticaria. The construct of the present invention can be delivered via a viral vector or a non-viral vector and can be used for gene therapy of allergic asthma-related diseases.
[0235] (5) The present invention optimizes the amino acid expression frame of ligelizumab according to the principles of human codon usage preference, mRNA secondary structure, appropriate GC content (avoiding excessive GC content), avoiding various cis elements involved in the transcription and translation process, avoiding the appearance of rare codons, splicing sites, etc., thereby greatly improving the expression level and stability of the target protein.
[0236] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and weight parts.
[0237] Unless otherwise specified, the materials and reagents in the specification of the present invention are commercially available products.
[0238] Example 1 Construction of rAAV8-Ligelizumab vector (detailed description of the construction process of the vector, with Figure 3 As an example, the structure
[0239] The entire construction process is as follows:
[0240] 1. GenScript synthetic IgE neutralizing antibody Ligelizumab
[0241] Ligelizumab structure: From the N-terminus to the C-terminus of the protein molecule, they are: heavy chain signal peptide (taking TPA signal peptide as an example, sequence: MDAMKRGLCCVLLLCGAVFVSP SEQ ID NO.: 22) - antibody heavy chain (HC) molecule (taking LigelizumabHC as an example) - Furin cleavage site - F2A self-cleavage 2A sequence - light chain signal peptide (taking L1 signal peptide, sequence: MDMRVPAQLLGLLLLWLSGARC SEQ ID NO.: 23) - antibody light chain (LC) molecule (taking Ligelizumab LC as an example) (see Figure 6 ). The heavy chain (HC) and light chain (LC) molecules of the sequence shown carry their own signal peptide sequences, and the heavy chain (SEQ ID NO.2) and light chain (Sequence ID No: 4) of the antibody molecule are connected by the Furin cleavage site and the self-cleavage 2A sequence, wherein the coding sequences of the antibody light chain and heavy chain are codon-optimized sequences.
[0242] 2. After the plasmid containing Ligelizumab gene (Ligelizumab-pUC57) and bacterial solution arrive, the bacterial solution containing the plasmid is revived in 5 ml of culture medium containing corresponding antibiotics and cultured overnight at 37°C and 200 rpm with shaking.
[0243] 3. Extract plasmid ligelizumab-pUC57. Plasmid electrophoresis (Marker: 1kb DNA Ladder) Figure 1 shown.
[0244] 4. Enzyme digestion of target gene fragment and vector fragment.
[0245] 1) Obtaining the target gene. Digest ligelizumab-pUC57 with AgeI-SalI-ScaI to obtain the complete ligelizumab structure. The size of the bands after digestion should be 2.2kb, 0.9kb, and 1.8kb. Recover the 2.2kb fragment. Figure 2 shown.
[0246] 2) Obtaining the vector part. Plasmid pAAV-CBH-MCS, structured as Figure 5 As shown, double digestion with Age I and Sal I was performed. The size of the band after digestion should be 3.9 kb and 0.9 kb. The 3.9 kb fragment was recovered.
[0247] pAAV-CBH-MCS nucleotide sequence:
[0248]
[0249] AGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACCTGCCTGAAA
[0250] TCACTTTTTTTCAGGTTGGACCGGTGCCACCATGGCCCTCCTTACGAACCTCCTGCCGTTGTGCTG
[0251] CCTGGCCCTCCTCGCCTTGCCAGCGCAGAGCCACGCCGAAGGCACGTTCACCTCCGACGTGAGC
[0252] AGCTACCTGGAGGGCCAGGCCGCGAAAGAGTTCATCGCTTGGCTCGTCAAGGGCGGAGGAGGA
[0253] GGCGGAGGAAGCGGCGGAGGAGGAAGCGGAGGCGGAGGTAGCGCCGAGAGCAAGTACGGCCC
[0254] TCCTTGTCCTCCCTGCCCTGCCCCAGAGGCCGCTGGAGGACCATCCGTGTTTCTGTTTCCCCCCAA
[0255] GCCTAAGGACACCCTGATGATCAGCAGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGC
[0256] CAGGAGGACCCTGAGGTGCAGTTCAATTGGTACGTGGATGGCGTGGAGGTGCACAACGCCAAGA
[0257] CAAAGCCCAGAGAGGAGCAGTTTAATAGCACCTACAGAGTGGTGTCCGTGCTGACCGTGCTGCA
[0258] CCAGGATTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTGTCCAATAAGGGCCTGCCCAGCAGC
[0259] ATCGAGAAGACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCTCAGGTGTACACACTGCCTC
[0260] CCTCCCAGGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCC
[0261] CAGCGATATCGCCGTGGAGTGGGAGTCCAACGGCCAGCCCGAGAATAACTACAAGACCACCCCT
[0262] CCTGTGCTGGATAGCGACGGCAGCTTTTTCCTGTACTCCAGACTGACCGTGGACAAGTCTAGATG
[0263] GCAGGAGGGCAACGTGTTTTCTTGTAGCGTGATGCACGAGGCCCTGCACAATCACTACACCCAG
[0264] AAGTCCCTGTCTCTGAGCCTGGGCTGAGTCGACGTTTATTTGTGAAATTTGTGATGCTATTGCTTT
[0265] ATTTGTAACCATCTAGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAA
[0266] GCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGAT
[0267] GTGGGAGGTTTTTTAAAGTTTAAACAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCG
[0268] CGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCGGCCTCAGTGAG
[0269] CGAGCGAGCGCGCAGCTGCCTGCAGG
[0270] Restriction enzyme digestion electrophoresis (Marker: 1kb DNA Ladder) is as Figure 3 shown.
[0271] 5. The target gene fragment and the vector part were ligated using Solution I, and heat-shocked and transformed into DH5α, and cultured at 37°C overnight.
[0272] 6. Pick a single colony for PCR verification.
[0273] Pick a single colony from the transformed plate and place it in 400 μl of LB medium containing the corresponding antibiotics, and culture it at 37°C with shaking at 200 rpm for 2 h.
[0274] Use the following two primers, shake culture 2h bacterial solution as template, and use Mix for PCR verification.
[0275] Upstream primer: ZY005-VL-F (5'→3': GGATAGCAAGGACAGCACATACTC)
[0276] Downstream primer: pBR322-R (5'→3':GTGAGCTATGAGAAAGCGCC)
[0277] The band size after PCR should be 736 bp.
[0278] PCR electrophoresis (Marker: DL2000 DNA Marker) Figure 4 shown.
[0279] 7. The bacterial solution containing the plasmid with the correct band size was sent for sequencing. The sequencing results showed that the plasmid was successfully constructed (see Figure 7 A, 7B).
[0280] The target gene sequence of the above vector can be translated as a complete precursor molecule in the cell. The self-cleavage 2A sequence and Furin cleavage site are cleaved in the cytoplasm to produce highly accurate heavy chain and light chain molecules. When the heavy chain and light chain molecules are secreted outside the cell, they are assembled into monoclonal antibody molecules with complete structure and function in the cell supernatant.
[0281] The present invention also found that similar effects can be achieved by replacing the self-cleavage 2A sequence and the Furin cleavage site with IRES.
[0282] Example 2: Packaging and purification of adeno-associated virus expressing Ligelizumab
[0283] The antibody gene AAV vector (pAAV-CBH-Ligelizumab), envelope plasmid AAV8 constructed in Example 1, whose nucleotide sequence is shown in SEQ ID NO: 25) and auxiliary plasmid (pHelper, whose nucleotide sequence is shown in SEQ ID NO: 26) were mixed and co-transfected into 293T cells, and the AAV vector was packaged in the 293T cell line. The transfection method is PEI cationic polymer-mediated transient transfection of eukaryotic cells. The transfection operation is performed according to the standardized operation recommended by the manufacturer, and the transfection scale is a 15cm cell culture dish. The supernatant was discarded 7h after transfection and replaced with 25ml of toxin-producing medium. Five days after the transfection was completed, the supernatant and cells were collected, centrifuged at 4200rpm / min for 10min, and the supernatant and cells were separated after centrifugation. Lysis solution and ribozyme were added to the cells, lysed and digested for 1h, and centrifuged at 10000g / min for 10min to obtain the lysate supernatant. The lysate supernatant and the culture medium supernatant were purified by affinity chromatography and aliquoted and frozen at -80°C for standby use.
[0284] Example 3: Expression detection after pAAV-CBH-Ligelizumab infected cells
[0285] The packaged adeno-associated virus was used to infect 293T cells. The culture supernatant of cells infected with adeno-associated virus was subjected to SDS-PAGE electrophoresis, and the expressed antibody was transferred to a PVDF membrane. Western blotting experiments were performed using HRP-labeled goat anti-human IgG Fc antibody as the secondary antibody. Experimental results (see Figure 8 ) showed that adeno-associated virus could effectively express Ligelizumab after transducing cells in vitro, and secrete mature Ligelizumab antibody protein into the cell culture supernatant.
[0286] Example 4: Functional verification of ligelizumab expressed by rAAV
[0287] Western Blot Verification of Ligelizumab Binding to IgE
[0288] ① Dilute the purchased omalizumab (42.1 μg / μl) to 1 μg / μl
[0289] ② Dilute the purchased human IgE protein (1μg / μl) to 20ng / μl
[0290] ③ Take out Protein G Agarose, mix well, and pipette 100 μl into three 1.5 ml centrifuge tubes. Wash three times with Binding Buffer (pH 5.0) (sediment by gravity, then carefully remove the supernatant).
[0291] Then, IgE, omalizumab, purified ligelizumab and PBS were added according to Table 1 below, and 60 μl of Binding Buffer was added to each, and binding was carried out at room temperature.
[0292] Mix gently every 0.5 h, and then allow Protein G Agarose to settle by gravity for a total of 2 h.
[0293] Table 1: Sample addition details
[0294]
[0295] After 2 hours, the sample was loaded, and the loading volume was 20 μl (when IgE was not bound, it was equivalent to adding 20 ng of IgE, and the volume of the medium was negligible.)
[0296] ④ Block with 5% skim milk and wash three times
[0297] ⑤ Add mouse anti-human IgE (Fc) secondary antibody for incubation and wash three times
[0298] ⑥Exposure.
[0299] Experimental results (see Fig. 9 ) showed that the purified Ligelizumab had the same effect as the purchased omalizumab, both could bind to human IgE, and could be used as a standard in subsequent experiments.
[0300] 3. Expression of pAAV-CBH-ligelizumab in mouse muscle cells C2C12.
[0301] The packaged pAAV-CBH-ligelizumab virus was used to infect C2C12 cells at different MOIs. The virus infection supernatant was collected, and the purified ligelizumab was used as a standard to detect the content of ligelizumab in the C2C12 supernatant.
[0302] The specific steps are as follows:
[0303] The ELISA enzyme-labeled plate was coated with commercial human IgE, the expression supernatant and purified ligelizumab standard were used as the primary antibody, HRP-labeled goat anti-human IgG Fc was used as the secondary antibody, TMB was used for color development, and the OD value at 450nm was detected by a microplate reader. The experimental results (Table 2) showed that pAAV-CBH-ligelizumab virus could effectively express anti-human IgE neutralizing antibodies after in vitro transduction of C2C12 cells, and secrete mature ligelizumab antibody protein into the cell culture supernatant.
[0304] Table 2 Expression levels of Ligelizumab after infection of cells at different MOIs
[0305]
[0306] Example 5: Expression of pAAV-CBH-ligelizumab viral vector in normal BALB / c mice
[0307] After the pAAV-CBH-ligelizumab viral vector in the experimental group (EG) and the saline group (NG) were administered to BALB / c mice by intramuscular injection, blood was collected from the eye sockets of the mice every week to obtain serum. The expression of Ligelizumab in the serum was detected by ELISA. The results showed (see Fig.10 , Table 3) In the in vivo experiment, the pAAV-CBH-Ligelizumab virus was able to normally express Ligelizumab in mice, and the expression level was significantly higher than that in the saline group.
[0308] Table 3 Ligelizumab antibody concentration in serum of normal BALB / c mice
[0309]
[0310] Example 6: Therapeutic effect of pAAV-CBH-ligelizumab viral vector on asthma model animals
[0311] The pAAV-CBH-ligelizumab viral vector was injected intramuscularly into IgE / FcεRI double humanized BALB / c mice 7 days before the first induction of the model (Day-7). 3 days before induction (Day-3), 150 μL of whole blood from humanized mice was collected and serum was separated; after 3 sensitization processes (intraperitoneal injection of OVA and aluminum hydroxide gel suspension for sensitization) and 7 stimulation processes (OVA aerosol stimulation to induce asthma model), the mice were killed on Day 28, and serum and bronchoalveolar lavage fluid were taken for the determination of IL-4, IL-5, IL-13, OVA-Specific IgE and total IgE. In addition, the white blood cells and eosinophils in the bronchoalveolar lavage fluid were counted respectively.
[0312] The specific scheme is shown in Table 4:
[0313] Table 4 Main research agenda
[0314]
[0315] The animals were randomly divided into 3 groups and administered according to Table 5:
[0316] Table 5 Animal grouping and drug administration
[0317]
[0318] Experimental results (see Fig.11 , Fig.12 ) showed that after administration, the number of eosinophils and total leukocytes in the alveolar lavage fluid of mice was significantly reduced, the secretion of Th2 cytokines was reduced, and the asthma symptoms were alleviated.
[0319] In summary of the above embodiments, the present invention fuses the heavy chain and light chain of the neutralizing antibody Ligelizumab for human IgE through F2A to form a simple and efficient expression framework. The experimental results show that the pAAV-CBH-ligelizumab viral vector can be efficiently expressed in cells or mice, and its product can bind to human IgE. In vivo experiments show that the pAAV-CBH-ligelizumab viral vector shows effective blood drug concentrations in model mice, and also shows a positive effect of reducing the number of eosinophils in animals and the secretion of Th2 cytokines.
[0320] Example 7 Construction of pKL-lenti-kan-CBH-ligelizumab vector
[0321] The synthetic IgE neutralizing antibody Ligelizumab expression cassette gene sequence was amplified by PCR using the plasmid ligelizumab-pUC57 as a template, and then connected to the lentiviral vector pKL-lenti-kan-CBH-WPRE ( Fig.13 ) between MluI and EcoRV. After the construction was completed and confirmed to be correct by sequencing, it was named pKL-lenti-kan-CBH-ligelizumab ( Fig.14 ).
[0322] Example 8 Lentivirus pKL-lenti-kan-CBH-ligelizumab packaging, purification and titer detection
[0323] The ligelizumab gene lentiviral expression vector pKL-lenti-kan-CBH-ligelizumab, the envelope plasmid (Vsvg) and the packaging plasmid (Rev, GagPol) constructed in implementation 7 were co-transfected into 293T cells (purchased from the American Type Culture Collection Center (ATCC), with a deposit number of CRL-3216), and the coagulation factor VIII gene therapy lentiviral vector was packaged in the 293T cell line. The transfection method was PEI cationic polymer-mediated transient transfection of eukaryotic cells, and the PEI cationic polymer was PEI-Max transfection reagent purchased from Polysciences (purchased from Polysciences, catalog number: 24765-1). The transfection operation was performed according to the manufacturer's recommended standardized operation, and the transfection scale was 10 cm2 cell culture dishes.
[0324] 48 hours after transfection, the lentiviral vector (transfected cell culture supernatant) was harvested. First, the cell debris was removed by centrifugation at 4000 rpm for 5 minutes at room temperature on a desktop bucket centrifuge, and then the virus particles were precipitated by centrifugation at 10000 g for 4 hours at 4°C. After removing the centrifugal supernatant, 1 ml of DMEM complete medium was added to the virus particle precipitate, and the virus particles were resuspended with a microinjector, and the prepared virus resuspension was aliquoted and frozen at -80 degrees for later use.
[0325] Different volumes of lentiviral vectors were inoculated into the human CD4+T cell line, MT4 cell line (purchased from Shanghai Suer Biotechnology Co., Ltd.) pre-plated in the plate in a 96-well cell culture plate. The cell culture supernatant infected with the reporter gene lentiviral vector EGFP (lentiviral vector packaged with pCCL-sin-pGK-EGFP according to the above method) was used as a positive control. The infection titer of the initial harvest of the lentiviral vector was calculated by quantitative PCR and flow cytometer data based on GFP signals by methods well known in the art. The primer probe sequences used for quantitative PCR are:
[0326] LTR-For primer:CTGTTGTGTGACTCTGGTAACT(SEQ ID NO:27)
[0327] LTR probe: 5'-AAATCTCTAGCAGTGGCGCCCG-3'(SEQ ID NO:28)
[0328] LTR-Rev primer: TTCGCTTTCAAGTCCCTGTT (SEQ ID NO: 29)
[0329] HK Forward primer 5'-GCTGTCATCTCTTGTGGGCTGT-3'(SEQ ID NO:30)
[0330] HK probe 5'-CCTGTCATGCCCACACAAATCTCTCC-3'(SEQ ID NO:31)
[0331] HK Reverse primer 5'-ACTCATGGGAGCTGCTGGTTC-3'(SEQ ID NO:32)
[0332] The LTR probe has a 6FAM fluorescent group at the 5' end and a MGB fluorescent group at the 3' end;
[0333] The HK probe has a CY5 fluorescent group at the 5' end and a BHQ2 fluorescent group at the 3' end.
[0334] The titer of lentivirus pKL-lenti-kan-CBH-ligelizumab was tested to be 1.09E+09TU / mL.
[0335] Example 9 Lentivirus pKL-lenti-kan-CBH-ligelizumab transduction cell expression detection
[0336] The lentivirus pKL-lenti-kan-CBH-ligelizumab was transduced into suspended 293T cells at a certain MOI (5). After 72 hours of culture, the supernatant was collected and the protein was purified using Protein A medium. After elution, it was concentrated. After concentration, PBS was used to replace the solvent so that the solvent was basically replaced with PBS. The concentration was measured using a BCA kit and adjusted to 250ug / ml. The cells were aliquoted and frozen in a -80 refrigerator for later use. After purification, SDS-PAGE was performed. The results are shown in Figure 15. Fig.15 The test results showed that the lentiviral vector was able to express ligelizumab in large quantities.
[0337] Example 10 Comparison of different 2A peptides in lentiviral vectors
[0338] The heavy chain and light chain of the pKL-lenti-kan-CBH-ligelizumab vector are connected by the Furin cleavage site and the F2A (SEQ ID NO: 33) self-cleavage peptide sequence. We also tested the effects of T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), and P2A (SEQ ID NO: 36) as self-cleavage peptides on the expression of ligelizumab.
[0339] F2A: VKQTLNFDLLKLAGDVESNPGP(SEQ ID NO:33)
[0340] T2A:EGRGSLL TCGDVEENPGP(SEQ ID NO:34)
[0341] E2A:QCTNYALLKLAGDVESNPGP(SEQ ID NO:35)
[0342] P2A:ATNFSLLKQAGDVEENPGP(SEQ ID NO:36)
[0343] By universal homologous recombination, F2A in pKL-lenti-kan-CBH-ligelizumab was replaced with T2A, E2A, and P2A, respectively, and after construction, they were named pKL-lenti-kan-CBH-ligelizumab-T2A, pKL-lenti-kan-CBH-ligelizumab-E2A, and pKL-lenti-kan-CBH-ligelizumab-P2A, respectively. Lentivirus pKL-lenti-kan-CBH-ligelizumab, lentivirus pKL-lenti-kan-CBH-ligelizumab-T2A, pKL-lenti-kan-CBH-ligelizumab-E2A, and pKL-lenti-kan-CBH-ligelizumab-P2A were packaged by the method in Example 8.
[0344] The above four viruses were inoculated into 293T cells. (24-well plate, 1.0E+5 cells / well), and each virus was transduced with four gradients: 10μl, 20μl, 40μl, 60μl, 80μl, 100μl. The supernatant and cells were collected after 72h. The cells were lysed, and the number of lentivirus copies (Vector Copy Number, VCN) infected in 293T cells was calculated by quantitative PCR data using methods well known in the art. The transduction supernatant with consistent VCN (about 4) was selected for Elisa detection (the specific detection method is described in Example 4). The results are shown in Table 6. F2A and T2A have the same effect, E2A is second, and P2A is the worst.
[0345] Table 6 Comparison of the expression of ligelizumab expression cassette by different self-cleaving 2A peptides
[0346]
[0347] Partial sequence information
[0348]
[0349]
[0350]
[0351]
[0352]
[0353]
[0354]
[0355]
[0356]
[0357]
[0358]
[0359]
[0360]
[0361]
[0362]
[0363]
[0364]
[0365]
[0366]
[0367]
[0368]
[0369] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. An expression cassette, characterized in that The expression cassette includes the following elements in sequence: a promoter, a first signal peptide coding sequence, a heavy chain coding sequence of an anti-IgE antibody, a linker coding sequence, a second signal peptide coding sequence and a light chain coding sequence of an anti-IgE antibody; The anti-IgE antibody is Ligelizumab; The linker includes a self-cleaving linker, and the self-cleaving linker is selected from at least one of F2A, T2A and E2A; Wherein, the nucleotide sequence of the heavy chain coding sequence of the IgE antibody is shown as SEQ ID NO: 2; the nucleotide sequence of the light chain coding sequence of the IgE antibody is shown as SEQ ID NO: 4; The amino acid sequence of F2A is shown in SEQ ID NO:33; the amino acid sequence of T2A is shown in SEQ ID NO:34; and the amino acid sequence of E2A is shown in SEQ ID NO:
35.
2. The expression cassette according to claim 1, characterized in that The linker consists of a self-cleaving linker and a Furin cleavage site.
3. The expression cassette according to claim 1, characterized in that The promoter is an enhanced promoter, and the promoter is selected from at least one of CMV, CBH, EF1α, CAG, CAGG, CASI, desmin, TMCK, MCK, MHCK7, PGK and TTR.
4. The expression cassette according to claim 1, wherein The amino acid sequence of the heavy chain of the IgE antibody is shown in SEQ ID NO: 3; And / or, the amino acid sequence of the light chain of the IgE antibody is as shown in SEQ ID NO:
5.
5. The expression cassette according to claim 1, characterized in that The expression cassette has a structure shown in Formula I from the 5' end to the 3' end: Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9 (Formula I) Wherein, each "-" is independently a bond or a nucleotide linking sequence; Z1 is the promoter; Z2 is the first signal peptide coding sequence; Z3 is the heavy chain coding sequence of the anti-IgE antibody; Z4 is the Furin cleavage site; Z5 is the coding sequence of the self-cleaving linker; Z6 is a second signal peptide coding sequence; and Z7 is the light chain coding sequence of the IgE antibody; Z8 is the woodchuck hepatitis virus regulatory element WPRE element; Z9 is the polyadenylation signal (polyA).
6. The expression cassette according to claim 1, wherein The nucleotide sequence of the expression cassette is shown in SEQ ID NO:
7.
7. A carrier, characterized in that The vector contains the expression cassette according to any one of claims 1 to 6.
8. The vector according to claim 7, characterized in that The vector is an adeno-associated virus AAV vector.
9. An adeno-associated virus vector, characterized in that: The adeno-associated virus vector contains the expression cassette according to any one of claims 1 to 6.
10. A host cell, characterized in that The method comprises a vector according to claim 7 or 8 or an adeno-associated virus vector according to claim 9, or an exogenous expression cassette according to any one of claims 1 to 6 is integrated into its chromosome.
11. Use of the vector according to claim 7 or 8, the adeno-associated virus vector according to claim 9, or the host cell according to claim 10, characterized in that: Used for preparing a preparation or composition, wherein the preparation or composition is used for treating allergic diseases, wherein the allergic diseases are selected from the following group: allergic asthma, chronic spontaneous urticaria or a combination thereof.
12. A pharmaceutical preparation, characterized in that The preparation contains (a) the vector according to claim 7 or 8, the adeno-associated virus vector according to claim 9, or the host cell according to claim 10, and (b) a pharmaceutically acceptable carrier or excipient.
13. A method for preparing a recombinant adeno-associated virus vector, characterized in that: The method comprises culturing the host cell as claimed in claim 10, thereby obtaining the recombinant adeno-associated virus vector.
14. A medicine box, characterized in that: include: (i) a first container, and an active ingredient (a) in the first container, wherein the active ingredient (a) is the vector according to claim 7 or 8, the adeno-associated virus vector according to claim 9, the host cell according to claim 10, or the pharmaceutical preparation according to claim 12.
15. The kit according to claim 14, wherein: The kit also includes: (ii) a second container, and an active ingredient (b) in the second container, wherein the active ingredient (b) is other drugs for treating allergic diseases or their active ingredients, and the allergic diseases are selected from the following group: allergic asthma, chronic spontaneous urticaria or a combination thereof.
